Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Vanderbilt University Medical Center, Department of Pharmacology and Chemistry, Nashville, Tennessee 37232-6600, USA.
ACS Chem Neurosci. 2012 Mar 21;3(3):149-50. doi: 10.1021/cn3000179.
BMS-708163 is a novel, sulfonamide containing γ-secretase inhibitor from Bristol-Myers Squibb Co. currently in Phase II clinical trials for the treatment of Alzheimer's disease (AD).
BMS-708163 是一种新型含磺酰胺的γ-分泌酶抑制剂，由 Bristol-Myers Squibb 公司研发，目前正处于治疗阿尔茨海默病（AD）的 II 期临床试验阶段。
